Figure 2.
Blood levels for ganciclovir over 12-hour dosing period (mean ± SD). Plasma samples were drawn 30 minutes prior to the dosing interval; at administration of study drug (T0); 30 minutes thereafter; and subsequently 1, 2, 3, 4, 6, 8, and 12 hours after dosing. GCV plasma levels (mean ± SD) were determined using high-pressure liquid chromatography and were used to generate pk profiles following administration of valganciclovir (V-GCV) and intravenous ganciclovir (IV-GCV). (A) Pk profiles for patients without intestinal graft-versus-host disease (I-GVHD; n = 22). (B) Pk profiles for patients with I-GVHD grades I-II (n = 5). One patient with I-GVHD grade III is not included. Time points are offset for clarity.
